The HER2/neu gene, which is overexpressed in 20 ± 30% of human breast tumors, encodes a receptor tyrosine kinase that functions through multiple signaling pathways to regulate the activity of nuclear transcription factors. We have reported that PEA3, an Ets family transcription factor, is overexpressed in HER2/Neuinduced breast tumors and their metastases. To account for the increased levels of PEA3 in these tumors we have suggested that HER2/Neu enhances PEA3 transcriptional activity, which then acts to stimulate expression of the PEA3 gene. This hypothesis is consistent with the occurrence of PEA3 binding sites in the PEA3 promoter and with the ability of PEA3 to transactivate this promoter. To learn whether HER2/Neu indeed regulates PEA3 activity we measured the capacity of constitutively-activated HER2/Neu to aect PEA3-dependent reporter gene expression. Coexpression of PEA3 and HER2/Neu stimulated PEA3-dependent reporter gene expression to a much greater extent than did either protein alone suggesting that HER2/Neu upregulates the transcriptional activity of PEA3. To de®ne the pathway whereby HER2/Neu functions we employed dominantnegative mutants of signaling proteins known to be downstream of HER2/Neu. Overexpression of Rap1a, a Ras-related protein capable of antagonizing Ras function, completely inhibited the ability of HER2/Neu to stimulate PEA3-dependent gene expression. Ras is known to stimulate at least two mitogen-activated protein kinase (MAPK) cascades, the extracellularregulated kinase (ERK) cascade and the stress-activated kinase (SAPK) or Jun kinase (JNK) cascade. Similarly, HER2/Neu activated both ERKs and SAPKs/JNKs in a Ras-dependent fashion. Dominant-inhibitory mutants in either the ERK or SAPK/JNK cascades partially inhibited HER2/Neu activation of PEA3-dependent gene expression. These ®ndings suggest that HER2/Neu regulates PEA3 activity through two dierent Rasdependent MAPK pathways.
Introduction
The HER2/neu proto-oncogene (also known as c-erbB-2) encodes a 185 kDa class I receptor tyrosine kinase that is structurally related to the epidermal growth factor receptor (EGFR). The EGFR family includes EGFR itself (c-erbB-1) as well as c-erbB-2, -3 and -4. Overexpression of the human HER2/neu gene is implicated in the genesis of a number of carcinomas aecting several dierent organs including the breast, ovary, stomach, colon, kidney, bladder and salivary gland (reviewed in Hynes and Stern, 1994) . In breast cancer overexpression of HER2/neu is associated with poor prognosis for the patient (Slamon et al., 1987) . Breast tumors overexpressing HER2/Neu have an increased propensity to metastasize and respond poorly to hormonal and chemotherapeutic agents. The HER2/Neu protein is synthesized at elevated levels in breast tumors as a consequence of both HER2/neu gene ampli®cation and transcriptional upregulation of those genes that are ampli®ed; transcriptional activation accounts for a 6 ± 8-fold increased abundance of HER2/neu mRNA molecules per gene copy number (Slamon et al., 1989; Liu et al., 1992; Kraus et al., 1987; King et al., 1989; Iglehart et al., 1990) . The enhanced rate of transcription of HER2/neu in breast tumor cells has been ascribed to the increased activity of transcription activators, including AP-2 (Hollywood and Hurst, 1993) and any one of several Ets proteins that regulate transcription initiation from the HER2/neu promoter (Scott et al., 1994) .
In rodents, mutations in the coding sequences of HER2/neu are also capable of eecting its oncogenic activation. Carcinogen-induced rat neuroectodermal tumors result from a base substitution mutation aecting sequences encoding the HER2/Neu transmembrane domain (DiMarco et al., 1990) . Similarly mammary tumors arising in transgenic mice engineered to express the wild type (wt) normal HER2/neu gene in their mammary epithelium acquire mutations in the HER2/neu transgene that aect the extracellular region of the protein (Siegel et al., 1994; Siegel and Muller, 1996) . Overexpression of the wt HER2/Neu protein is sucient to transform mouse 3T3 ®broblasts in culture (DiFiore et al., 1990; Hudziak et al., 1987; DiMarco 1990) . Both activating mutations and overexpression of HER2/Neu facilitate its dimerization thereby stimulating its intrinsic tyrosine kinase activity (Bargmann et al., 1986; Siegel and Muller, 1996; Weiner et al., 1989) .
Under normal physiological conditions, the HER2/ Neu protein is activated by ligand binding, which eects its homodimerization or heterodimerization with other members of the EGFR family, and subsequent autophosphorylation at multiple, speci®c tyrosine residues in the intracellular cytoplasmic portion of the protein (reviewed in Hynes and Stern, 1994) . These phosphotyrosines serve as binding sites for downstream eector proteins bearing Src homology 2 (SH2) or phosphotyrosine binding/interacting (PTB/PTI) do-mains (reviewed in Pawson, 1995) . HER2/Neu eectors include: GRB-2; GRB-7; SHC; phospholipase C gamma; phosphatidylinositol 3'-kinase; Ras GAP; cSrc; and protein tyrosine phosphatase (PTPase) 1d. Recruitment of these proteins to the receptor enhances their activity or positions them proximal to their substrate targets in the plasma membrane. The consequence of this is to activate several distinct downstream signal transduction pathways (reviewed in Hynes and Stern, 1994; Pawson, 1995) .
One of the pathways downstream of HER2/Neu is the Ras signaling pathway. Ras is activated at the plasma membrane following recruitment of the adapter proteins SHC and Grb2/SOS to particular phosphotyrosines in the HER2/Neu receptor (Xie et al., 1995; Ricci et al., 1995; Kavanaugh et al., 1995) . SHC associates with Grb2, which normally exists in a stable complex with mSOS1 and mSOS2, two mammalian homologues of Drosophila SOS. SOS exchanges GDP for GTP on Ras thereby activating Ras (Janes et al., 1994) . Subsequently, GTP bound Ras activates protein serine/threonine kinase cascades including the ERK (Janes et al., 1994; Ben-Levy et al., 1994) and SAPK/ JNK cascades (Pinkas-Kramarski et al., 1996) . Activated MAP kinases directly phosphorylate and elevate the activity of a subset of nuclear transcription factors including members of the Jun, Fos and Ets families resulting in changes in gene expression (reviewed in Treisman et al., 1996) .
The mouse PEA3 gene is transcribed at low basal levels in normal mammary epithelium (Xin et al., 1992) . However, expression of PEA3 is substantially elevated in mammary tumors and lung metastases that develop in transgenic mice genetically modi®ed to express normal HER2/Neu in their mammary epithelial cells suggesting a role for PEA3 in HER2/Neu-induced mammary tumorigenesis (Trimble et al., 1993) . PEA3 may also play a role in human breast cancer. The human PEA3 gene is transcriptionally upregulated in breast tumor cell lines (Scott et al., 1994) and in 93% of HER2/Neu-positive human breast tumors (Benz et al., 1997) . To account for the increased abundance of PEA3 transcripts in HER2/neu-induced mammary tumors we have suggested that the HER2/Neu tyrosine kinase enhances transcription of the PEA3 gene by stimulating the activity of nuclear transcription factors that act at the PEA3 promoter (Trimble et al., 1993) . Recent data suggests that the PEA3 protein itself can regulate transcription of the PEA3 gene by binding to sites in the PEA3 promoter (Benz et al., 1997) . These ®ndings suggested the possibility that elevated levels of PEA3 in mouse and human breast tumors might result from HER2/Neu-mediated increased PEA3 transcriptional activity. Once activated, the PEA3 protein may upregulate transcription of the PEA3 gene thereby leading to increased amounts of its transcript and protein product.
PEA3 is the founding member of a subfamily of ets genes that include ER81 (Brown and McKnight, 1992) and ERM (Monte et al., 1994) . All Ets proteins contain an evolutionarily-conserved, *85 amino acid ETS DNA binding domain (Xin et al., 1992; Brown and McKnight, 1992; Monte et al., 1994; Karim et al., 1990) ; subfamily members possess nearly identical ETS domains and share additional regions of sequence similarity (Karim et al., 1990; Macleod et al., 1992; Seth et al., 1992; Wasylyk et al., 1993) . Ets proteins bind to related *10 base pair DNA sequence elements in the promoters of target genes where they act to regulate transcription. Several candidate Ets target genes have been reported based largely on the occurrence of ETS binding sites in their upstream regulatory regions (Matrisian, 1994; Higashino et al., 1995; Kaya et al., 1995 Kaya et al., , 1996 Delattre et al., 1992) . A large proportion of these encode matrix-degrading proteolytic enzymes, whose unregulated expression has been associated with the propensity of tumor cells to metastasize (Matrisian, 1994) . PEA3 can regulate the transcription of several such proteinases including the matrix metalloproteinases (MMP) collagenase-IV/ gelatinase B (MMP-9), matrilysin (MMP-7), and stromelysin-3 (MMP-11), and the serine protease urokinase-type plasminogen activator (Matrisian, 1994; Higashino et al., 1995) . In agreement with this, forced expression of PEA3 in the non-metastatic human MCF-7 breast cancer cell line leads to an increase in its invasive and metastatic properties in cell culture and in immunocompromised mice (Kaya et al., 1996) . These ®ndings raise the prospect that elevated levels of PEA3 in HER2/Neu-positive breast tumors may account for their increased metastatic potential.
Ets genes, including PEA3, have been implicated in cancer in both humans and experimental animals (Kaneko et al., 1996; Urano et al., 1996; Delattre et al., 1992; Jeon et al., 1995) . In humans, chromosomal translocations found in Ewing's sarcoma and related soft-tissue tumors result in the expression of Ets fusion proteins that possess increased transcriptional activity by comparison to the parental Ets protein suggesting that it is the increased expression of their downstream target genes that is critical for tumorigenesis (Bailly, 1994; Lessnick et al., 1995) . Infection of mice with certain retroviruses (various strains of Freind virus) result in proviral insertions that transcriptionally activate expression of the normal Fli-1 or Spi-1 (PU.1) genes leading to the transformation of immature myeloid stem cells (Ben-David and Bernstein, 1991) . Whereas the involvement of ets genes in human breast cancer is largely unexplored, the fact that the PEA3 gene is overexpressed in HER2/Neu-positive human and mouse breast tumors suggests that it may play a role in this disease (Trimble et al., 1993; Benz et al., 1997) . To explore the link between overexpression of HER2/neu and PEA3 in breast tumorigenesis, we measured the ability of the HER2/Neu receptor tyrosine kinase to aect the transcriptional activity of PEA3. Our ®ndings suggest that HER2/Neu functions through two dierent Ras-dependent MAPK pathways to regulate PEA3 transcriptional activity. Transcriptionally-activated PEA3 likely stimulates its own expression thus accounting for the increased levels of PEA3 found in HER2/Neu-positive breast tumors.
Results

HER2/Neu stimulates PEA3-dependent gene expression
To learn whether the activity of PEA3 is regulated by the HER2/Neu receptor tyrosine kinase we enquired whether normal and constitutively-activated rat HER2/ Neu were capable of enhancing PEA3-dependent gene expression. To this end we transfected COS cells with a PEA3 reporter plasmid encoding luciferase, and eector plasmids coding for murine PEA3 and either normal or constitutively-activated rat HER2/Neu. Luciferase activity served as a measure of reporter gene expression. The arti®cial promoter in the PEA3 reporter plasmid comprises three head-to-tail tandem copies of the PEA3 binding site upstream of a synthetic TATA element modeled after that of the adenovirus type 2 major late promoter (Xin et al., 1992) . We have shown previously that Ets proteins endogenous to mammalian cells or PEA3 ectopically expressed in these cells stimulate expression of the reporter gene dependent on the occurrence of multiple, functional PEA3 binding sites in the arti®cial promoter (Xin et al., 1992) . Mutations in the central GGA motif of the PEA3 recognition site compromise PEA3 binding and PEA3-dependent reporter gene expression (Xin et al., 1992) .
In serum-starved COS cells expression of PEA3 from the eector plasmid enhanced luciferase expression from the reporter plasmid about twofold greater than the endogenous activity ( Figure 1a compare lanes 1 and 2). Cotransfection of the PEA3 reporter with the eector plasmids encoding either normal or constitutively-activated HER2/Neu only marginally aected luciferase expression suggesting that HER2/Neu did not alter the activity of those Ets proteins endogenous to COS cells (compare lanes 1, 3 and 5). By contrast, coexpression of PEA3 with normal HER2/Neu (lane 4) or constitutively-activated HER2/Neu (lane 6) led to a sixfold and 13-fold increase in reporter gene expression respectively. The extent of reporter gene expression resulting from coexpression of PEA3 and HER2/Neu substantially exceeded that due the sum of the activities eected by PEA3 and HER2/Neu individually. This synergistic eect of HER2/Neu and PEA3 likely resulted from HER2/Neu mediated stimulation of PEA3 transcriptional activity. It is noteworthy that constitutively-activated HER2/Neu was a much better activator of PEA3-dependent reporter gene expression than was its normal counterpart. This probably re¯ects the greater intrinsic tyrosine kinase activity of constitutively-activated HER2/Neu (Bargmann and Weinberg, 1988a,b; Stern et al., 1988) .
To determine whether HER2/Neu aected the abundance of PEA3 in transfected COS cells we measured the amount of endogenous and ectopicallyexpressed PEA3 protein in the absence and presence of coexpressed normal or constitutively-activated HER2/ Neu. As observed previously (O 'Hagan et al., 1996) , endogenous simian PEA3 was not detected in COS cells ( Figure 1b , lane 1); the monoclonal antibody used in PEA3 immunoblots is capable of detecting both simian and human PEA3 (O 'Hagan et al., 1996) . Based on the amount of protein extract analysed and the known sensitivity of the PEA3 monoclonal antibody we estimate that there are fewer than 500 molecules of PEA3 per COS cell (O 'Hagan et al., 1996) . Expression of normal or constitutively-activated HER2/Neu did not signi®cantly alter the amount of either the endogenous PEA3 ( Figure 1b compare lanes 1, 3 and 5) nor that of ectopically-expressed PEA3 in COS cells (compare lanes 2, 4 and 6). Multiple repetitions of this experiment yielded similar results (data not shown). Taken together these data suggest that both forms of HER2/Neu elevated PEA3-dependent gene expression by augmenting the transcriptional activity of PEA3 and not its abundance. Hence PEA3 appears to be a downstream target of the HER2/Neu receptor tyrosine kinase. Because PEA3 was not detectably expressed in COS cells, and because the endogenous activity comprised only a small fraction of the total activity acting through the PEA3 binding site following transfection with the PEA3 eector, we have chosen to only brie¯y describe the eect of the various signaling proteins on this background activity in subsequent sections.
HER2/Neu regulation of PEA3 activity requires Ras
HER2/Neu is known to activate a number of downstream signaling pathways that aect the activity of nuclear transcription factors (Hynes and Stern, 1994; Galang et al., 1996) . Initially we enquired whether HER2/Neu functioned through Ras to stimulate PEA3 transcriptional activity. To this end we examined the ability of Rap1a, a dominant inhibitor of Ras function (Kitayama et al., 1989) , to aect the ability of HER2/ Neu to enhance PEA3-dependent gene expression. In these experiments constitutively-activated HER2/Neu increased PEA3-dependent gene expression approximately sixfold (Figure 2a , compare lanes 2 and 4). Coexpression of Rap1a with constitutively-activated HER2/Neu and PEA3 completely blocked HER2/Neustimulated, PEA3-dependent gene expression (compare lanes 4 and 10). We also directly tested the ability of constitutively-activated Ha-Ras (Ha-RasV12) to aect PEA3-dependent gene expression. Ha-RasV12 stimulated PEA3-mediated gene expression to essentially the same extent as did HER2/Neu (compare lanes 2, 4 and 6). Rap1a completely blocked this eect of Ha-RasV12 (compare lanes 6 and 12). Coexpression of Rap1a with PEA3 in the absence of ectopic HER2/Neu had no eect on PEA3-dependent gene expression suggesting that Rap1a does not aect the basal activity of PEA3
nor that of the general transcriptional machinery (compare lanes 2 and 8).
Expression of constitutively-active HER2/Neu, HaRasV12 or Rap1a did not aect the levels of PEA3 expressed in transfected COS cells (Figure 2b ). Rap1a also did not aect the amount of HER2/Neu or HaRasV12 expressed in the transfected COS cells (data not shown). Hence the eect of Rap1a was to abrogate HER2/Neu signaling to PEA3. Because Rap1a inhibits Ras function these ®ndings imply that Ras is required for HER2/Neu upregulation of PEA3 transcriptional activity.
HER2/Neu activates both the ERK and SAPK/JNK cascades in COS cells
Recent evidence suggests that Ras signals through multiple eectors to activate the Ras-related, GTPbinding protein Rac1 (and Cdc42), and the serinethreonine kinase Raf-1 (Minden et al., 1994) . The pathway downstream of Raf is well de®ned (Marshall, 1994) ; Raf phosphorylates and activates MEK1, which in turn phosphorylates and activates ERK1 and ERK2. Signaling events downstream of Rac1 and Cdc42 are less well understood; recent evidence suggests that these proteins indirectly activate the SAPK/JNK family (Coso et al., 1995; Minden et al., 1995) perhaps by direct activation of the budding yeast Ste20p homologue PAK1 (Bagrodia et al., 1995; Zhang et al., 1995; Polverino et al., 1995) . PAK1 activates MEK kinase-1 (MEKK1) (Qiu et al., 1995; Lange-Carter and Johnson, 1994) , which phosphorylates and activates the dual speci®city kinase SEK1 (Hill and Treisman, 1995) . SEK1, also known as JNKK1 or MKK4 , acts in turn to phosphorylate and activate members of the SAPK/ JNK subfamily of MAPKs. Hence, both the ERKs and SAPK/JNKs can be activated by Ras-dependent kinase cascades.
To determine whether HER2/Neu aected the kinase activity of both ERKs and the JNKs/SAPKs in COS cells we transfected eector plasmids encoding them with the eector plasmid coding for constitutively-activated HER2/Neu and assayed the resulting endogenous ERK2 and JNK1 kinase activity in cell lysates. ERK2 or JNK1 was imunoprecipitated from the lysates using speci®c polyclonal antibodies, and in vitro immune-complex kinase assays were performed using myelin basic protein (MBP) or GST-Jun as substrates for ERK2 and JNK1 respectively. Constitutively-activated HER/Neu stimulated the kinase activity of both JNK1 (Figure 3a compare lanes 1 and 2) and ERK2 (Figure 3b compare lanes 1 and 2) . The speci®c activity of these MAPKs was increased by expression of HER2/Neu in COS cells because similar amounts of the kinases were expressed following transfection of COS cells with the various eector plasmids (Figure 3a and b) .
To learn whether activation of both ERK2 and JNK1 by HER2/Neu was Ras-dependent we coexpressed Rap1a with constitutively-active HER2/Neu and subsequently performed immune-complex kinase assays as described above. Rap1a nearly completely blocked HER2/Neu stimulation of the kinase activity of JNK1 (Figure 3a compare lanes 2 and 3) and ERK2 (Figure 3b compare lanes 2 and 3) , without HER2/Neu functions through two independent MAPK pathways to stimulate PEA3 transcriptional activity
To learn whether HER2/Neu also acted through the ERK and/or SAPK/JNK cascades to stimulate PEA3 activity we assessed the ability of dominant-inhibitory mutants in each pathway to aect HER2/Neumediated activation of PEA3-dependent gene expression. In these experiments constitutively-activated HER2/Neu increased PEA3-dependent gene expression approximately sevenfold (Figure 4a compare lanes 1 and 2). Coexpression of increasing amounts of a kinase-inactive mutant of Raf1 (Raf K375A) with PEA3 and HER2/Neu partially inhibited HER2/Neustimulated, PEA3-dependent gene expression in a dose dependent manner (lanes 2 ± 6). The expression vector lacking the Raf K375A coding sequences, when used at the same concentrations, had no eect on HER2/Neustimulated, PEA3-dependent gene expression suggesting that the inhibition of luciferase expression was mediated by the Raf K375A protein (data not shown).
At the highest concentrations of dominant-negative Raf used in these experiments the maximal inhibition of HER2/Neu-activated, PEA3-dependent gene expression achieved was somewhat less than 50% that of the control (compare lanes 2 and 6). Another kinase-inactive, dominant-negative mutant in the ERK cascade, MEK K97M, also partially inhibited the ability of HER2/Neu to stimulate PEA3-dependent gene expression in a dose-dependent fashion (compare lane 2 to lanes 7 ± 10). In this instance too the empty expression vector lacking the coding sequences for dominant-negative MEK did not aect HER2/Neu-stimulated, PEA3-dependent gene expression at the highest doses used in these experiments suggesting that the MEK K97M protein product was required to reduce PEA3-dependent gene expression (data not shown). Cotransfection of the eector plasmids encoding either dominant-negative Raf or dominant-negative MEK at doses that led to maximal inhibition of PEA3-dependent gene expression did not aect the amount of PEA3 expressed from the PEA3 eector plasmid (Figure 4b ). Taken together these results show that individually the dominantnegative protein kinases in the ERK cascade only partially blocked activation of PEA3 transcriptional activity by HER2/Neu.
Because dominant-negative mutants in the ERK cascade partially reduced the ability of HER2/Neu to stimulate PEA3-dependent gene expression, yet inhibitors of Ras function (Rap1a) completely blocked HER2/Neu-mediated activation of PEA3, it seemed likely that HER2/Neu activated another Ras-dependent signaling pathway in addition to the ERK cascade to regulate PEA3 transcriptional activity. Because constitutively-activated HER2/Neu functioned through Ras to stimulate SAPK/JNK activity in COS cells (Figure 3) , we enquired whether dominant-negative inhibitors in the SAPK/JNK pathway aected regulation of PEA3 activity by HER2/Neu. To this end we employed dominant-negative mutants of Rac1 (Rac1N17) and SEK1 (SEK-AL). Rac1 is known to act downstream of Ras to regulate the SAPK/JNK pathway; therefore inhibitors of its function should abrogate signaling from HER2/Neu to the SAPKs/ JNKs. The ability of constitutively-activated HER2/ Neu to stimulate PEA3-dependent gene expression was inhibited by dominant-negative Rac1 to approximately 50% that of the control (Figure 5a compare lane 2 with lanes 3 ± 6). Increasing the amount of the Rac1N17 eector plasmid beyond that shown in Figure 5a did not further inhibit HER2/Neu-stimulated, PEA3-dependent gene expression (data not shown). Similarly, dominantnegative SEK (SEK-AL) reduced HER2/Neu-stimulated, PEA3-dependent gene expression to approximately 50% of the control at the highest doses tested (compare lane 2 to lanes 7 ± 10). Dominant-negative The ability of HER2/Neu to stimulate ERK2 activity in the absence and presence of Rap1a was determined by immune-complex kinase assay using MBP as substrate. The immunoblot (1B) illustrates the levels of EK2 expressed mutants of Rac1 and SEK1 did not aect the amount of PEA3 expressed in the transfected COS cells at those concentrations of the dominant-negative eector plasmids that resulted in maximal inhibition of HER2/ Neu-mediated, PEA3-dependent gene expression (Figure 5b) . These data are consistent with the interpretation that dominant-negative mutants in the SAPK/JNK pathway partially inhibit the ability of constitutivelyactivated HER2/Neu to enhance PEA3-dependent gene expression by aecting signaling through the SAPK/ JNK module. Hence it appears that HER2/Neu regulates PEA3 transcriptional activity by signaling through Ras and at least two distinct downstream MAPK cascades.
Discussion
HER2/Neu directly acts through multiple eectors to initiate dierent biochemical pathways culminating in changes in the activity of several classes of transcription factors. Analyses of the ability of HER2/Neu to regulate expression of transcription factor familyspeci®c reporter genes suggest that the transactivation potential of one or more members of the AP-1, Ets and NF-kB families is stimulated by this receptor tyrosine kinase (Galang et al., 1996) . The activity of c-Jun (BenLevy et al., 1994) and Ets-2 (Galang et al., 1996) is increased by constitutively-activated HER2/Neu. HER2/Neu-mediated upregulation of Ets-2 activity requires Ras and Raf function, and is eected by direct phosphorylation of Ets-2 at a candidate MAPK phosphorylation site near its amino-terminus (Galang et al., 1996) . This coupled with the observation that constitutively-activated HER2/Neu upregulates ERK-1 and -2 activity (Janes et al., 1994; Ben-Levy et al., 1994) raises the possibility that activated ERKs directly phosphorylate Ets-2 thereby altering its transcriptional activity (Galang et al., 1996) . The physiological signi®cance of upregulation of the activity of Ets transcription family members by HER2/ Neu is emphasized by the observation that altered Ets-1 and Ets-2 proteins comprising an ETS DNA binding domain, but lacking transactivation domains, inhibit transformation by constitutively-activated HER2/Neu (Galang et al., 1996) . This observation demonstrates the seminal contribution of Ets proteins to HER2/Neuinduced oncogenic transformation. However, it is not clear which member(s) of the Ets family is integral to HER2/Neu-mediated oncogenesis because the function of all Ets proteins is very likely compromised by such dominant-negative Ets-1 and -2 proteins. Dierent Ets proteins have similar DNA binding speci®cities (Karim, 1990; Macleod et al., 1992; Seth et al., 1992; Wasylyk et al., 1993) . Hence overexpression of the ETS DNA binding domain of any particular Ets protein is likely to reduce expression of the target genes of many dierent Ets proteins in aected cells. This is substantiated by the ®nding that overexpression of dierent, distantly-related, dominant-negative Ets proteins block transformation by oncogenic Ras (Wasylyk et al., 1994) . Clearly, it will be important to identify the physiologically-relevant Ets target protein(s) downstream of HER2/Neu in both normal and cancer cells.
The fact that PEA3 is expressed at low basal levels in the mammary gland (Xin et al., 1992) , but is upregulated in mouse (Trimble et al., 1993) and human mammary tumors (Benz et al., 1997) that overexpress HER2/Neu suggests that it may be a biologicallyrelevant downstream target of this receptor tyrosine kinase in mammary epithelial cells. The occurrence of conserved, functional PEA3-binding sites in the human, rat and mouse HER2/neu promoters (White and Hung, 1992) , which are known to be required for optimal expression of the gene, also suggests a role for PEA3 in regulating HER2/neu transcription (Scott et al., 1994) . Consistent with this contention is the ®nding that the endogenous mouse HER2/neu gene is overexpressed in mammary tumors that express a rat HER2/neu transgene in their mammary epithelium (Trimble et al., 1993) . Furthermore, we have recently shown that PEA3 is capable of transactivating the human HER2/neu promoter (Benz et al., 1997) . These ®ndings strongly suggests a role for PEA3 in HER2/ Neu-mediated oncogenesis.
To account for increased PEA3 and HER2/neu transcripts in HER2/Neu-induced mammary tumors we have suggested that the HER2/Neu receptor tyrosine kinase regulates the activity of PEA3, which then acts to transcriptionally upregulate both the PEA3 and HER2/neu genes (Trimble et al., 1993) . In this study we directly addressed whether the activity of PEA3 is regulated by HER2/Neu and we used dominant-negative signaling proteins to identify the signaling pathway(s) downstream of HER2/Neu required for such regulation. Both normal and constitutively-activated HER2/Neu stimulated PEA3-dependent reporter gene expression. Constitutivelyactivated HER2/Neu increased PEA3-dependent gene expression to a greater extent than did its normal counterpart consistent with its enhanced tyrosine kinase activity (Bargmann et al., 1986) . The eect of HER2/Neu was to increase the transcriptional activity of PEA3 because both HER2/Neu proteins only altered reporter gene expression when co-expressed with PEA3; the magnitude of this response was much greater than the sum of the increase in reporter gene expression eected by PEA3 and HER2/Neu individually. Neither form of HER2/Neu signi®cantly aected the abundance of ectopically-expressed PEA3 in COS cells.
Rap1a, an inhibitor of Ras signaling, blocked HER2/Neu upregulation of PEA3 transcriptional activity, but it did not alter either the amount of HER2/Neu or PEA3 expressed from the eector plasmids. Similarly two dominant-inhibitors acting in the ERK cascade (kinase-inactive Raf and MEK1), and two dominant-inhibitors (Rac1N17 and a form SEK1 incapable of being activated) functioning in the SAPK/JNK pathway partially inhibited HER2/Neu stimulation of PEA3 transcriptional activity without aecting the abundance of HER2/Neu and PEA3 expressed in cells. The complete inhibition of HER2/ Neu upregulation of PEA3 transcriptional activity achieved by Rap1a suggests that HER2/Neu acts principally through Ras to eect changes in the activity of PEA3. By contrast, partial inhibition of HER2/Neu-stimulated PEA3 activity by dominantnegative elements in each MAPK cascade implies that HER2/Neu signals by both pathways to regulate PEA3 activity, and that inhibition of each pathway individually is not sucient to completely abrogate signaling to this downstream target. Consistent with this interpretation was the observation that HER2/Neu was able to stimulate the kinase activity of ERK2, as well as that of JNK1 in COS cells in a Ras-dependent fashion.
The mechanism whereby the activity of PEA3 is regulated by HER2/Neu and the downstream ERK and SAPK/JNK cascades is not yet clear. Recent experiments reveal that Ras, a downstream eector of HER2/Neu, stimulates the transcriptional activity of GAL4-PEA3 chimeras implying that the transactivation function of PEA3 is regulated by this signaling protein (data not shown). Experiments are underway to learn whether the subcellular distribution and DNA binding activity of PEA3 are aected by HER2/Neu and Ras. Currently, we do not know whether PEA3 or an unknown partner is directly targeted by HER2/Neuactivated signaling proteins. Commonly Ets proteins subject to regulation by activators of MAPK cascades are directly phosphorylated by MAPKs resulting in changes in their transcriptional activity (reviewed in Treismann, 1996) . It is noteworthy that PEA3 is a phosphoprotein; phosphorylation occurs in vivo at serine residues; and PEA3 contains eight potential MAPK phosphorylation sites (S/T,P) all of which are proline-directed serines located outside of its ETS DNA binding domain (O 'Hagan et al., 1996) . PEA3 is eciently phosphorylated in vitro by both ERKs and SAPKs/JNKs suggesting that it might be a direct substrate of these kinases in vivo (data not shown).
Clearly it will be interesting to learn whether the activity of PEA3 is indeed regulated by phosphorylation, whether this is eected by MAPKs, and whether the same or dierent sites in PEA3 are phosphorylated in response to activation of ERKs and SAPKs/JNKs.
The role of PEA3 in HER2/Neu-mediated tumorigenesis is presently unclear. PEA3 can regulate transcription of the HER2/neu and PEA3 genes (Benz et al., 1997) . Hence we imagine that genetic alterations (gene ampli®cation and mutations) leading to upregulation of expression or activity of HER2/Neu will result in increased PEA3 transcriptional activity. Activated PEA3 may then enhance transcription of its target genes, which likely include the HER2/neu and PEA3 genes. Upregulation of PEA3 activity and abundance in tumor cells may also enhance the invasive and metastatic potential of these cells. PEA3 is overexpressed in metastatic mammary tumors (Trimble et al., 1993) , and ectopic overexpression of PEA3 in human mammary MCF-7 cells, which express very low levels of HER2/Neu and PEA3, endows these cells with invasive and metastatic properties (Kaya et al., 1996) . This may result in part from PEA3-mediated transcriptional activation of genes encoding matrixdegrading proteinases (Higashino et al., 1995; Kaya et al., 1996; Kaneko et al., 1996) . Hence the consequences of HER2/Neu-mediated activation of PEA3 transcriptional activity may be to sustain high level expression of the HER2/neu and PEA3 genes, as well as that of other PEA3 target genes whose products facilitate tumor cell invasion and metastasis. If this model is substantiated, it may have important implications in the design of new therapeutic agents and regimens to treat patients with HER2/Neu-positive tumors.
Materials and methods
Recombinant plasmids
The arti®cial PEA3-responsive promoter in the reporter plasmid pPEA3 3 LUC comprises a synthetic TATA box corresponding to that of the adenovirus two major late promoter, and 3 tandem head-to-tail copies of the PEA3 binding site (shown in bold) (5'-GATCCAGGAAGTGAC-3') from the polyomavirus enhancer (Xin et al., 1992) . Normal and constitutively-activated forms of rat HER2/ Neu were expressed from the Moloney murine leukemia virus promoter of pJ4O (Siegel et al., 1994; Morgenstern and Land, 1990) . The constitutively-activated form of HER2/Neu contains an amino acid substitution (V664E) in the transmembrane region of the protein (Bargmann et al., 1986) . Rap1a and dominant-negative mutants of Raf1 (Raf K375A) and Rac1 (Rac1N17) were expressed from the SV40 early promoter of pcEXV3 (Miller and Germain, 1986) . Dominant-negative mutants of MEK1 (MEK K97M) and SEK1 (SEK1-AL) were expressed from the Moloney murine leukemia virus long terminal repeat in pMCL (Mansour et al., 1994) , and from the human CMV promoter of pcDNA3 (Yan et al., 1994) respectively.
Cell culture and transfections
COS cells were maintained essentially as described previously (O'Hagan et al., 1996) . These cells were transfected with 0.3 mg of the PEA3 reporter plasmid (pPEA3 3 LUC), 0.6 mg of the PEA3 eector plasmid (pRc/ RSV-PEA3), and 0.3 mg of an expression vector encoding the normal or constitutively-activated form of rat HER2/ Neu as indicated in the ®gure legends. Expression vectors encoding Rap1a and dominant-negative mutants of Raf, Rac1, MEK1 and SEK1 were transfected at the concentrations speci®ed in the ®gures. The total DNA concentration was adjusted to 2.5 mg per 35 mm Petri dish with herring sperm DNA where required. Transfections were carried out using the LipofectAMINE reagent (Life Technologies) for 5 h and thereafter the cells were allowed to recover for 10 h in DME supplemented with 10% fetal bovine serum, and then were starved of serum for 48 h before lysis.
Luciferase assays
Transfected, serum-deprived COS cells were lysed for 15 min in reporter lysis buer (Promega); relative luciferase activity was determined using the Promega luciferase assay reagent and a luminometer.
Immunoblots
To assay the amount of PEA3, HER2/Neu, ERK2 or JNK1 protein expressed after transfection, the cells were collected and lysed in ice cold buer containing 1% NP40, 50 mM Tris-HCl (pH 7.4), 5 mM EDTA, 400 mM NaCl, 2 mg/ml PMSF, 1 mg/ml each of leupeptin, pepstatin and aprotinin. Lysates were clari®ed by centrifugation for 5 min at 12 000 r.p.m. in a microcentrifuge. The supernatants were boiled for 5 min in loading buer (2% SDS, 50 mM Tris-HCl (pH 7.4), 65 mM b-mercaptoethanol, 0.1% bromophenol blue and 10% glycerol), resolved by electrophoresis in 9% SDS-polyacrylamide gels, and transferred to PVDF membranes by electroblotting. All proteins were detected using the BM Chemiluminescence system (Boehringer Mannheim). The antibodies used to detect the various proteins were as follows: PEA3 ± a murine monoclonal antibody (MP-13); HER2/Neu ± the Neu-Ab3 antibody (Oncogene Science); ERK2 ± an anti-ERK2 rabbit polyclonal antibody (Transduction Labs); and JNK1 ± a murine monoclonal antibody directed against human JNK1 (Pharmingen).
Immune-complex kinase assays
To measure the protein kinase activity associated with the various MAPKs, transfected COS cells were collected and lysed in ice-cold buer containing 1% NP40, 50 mM TrisHCl, pH 7.4, 5 mM EDTA, 400 mM NaCl, 2 mg/ml PMSF, 1 mg/ml each of leupeptin, pepstatin and aprotinin, 2 mM sodium orthovanadate, 50 mM sodium¯uoride, 20 mM bglycerophosphate, and 0.1 mg/ml okadaic acid. ERK2 and JNK1 were immunoprecipitated using the antibodies described above. Immune-complex kinase assays were performed as described by Hill and Treismann (1995) .
